Newly Discovered Late Clinical Stage Biopharma Vendor with Potentially Revolutionary Breakthroughs & 4 Growing Companies to C...

Fuse Science, Inc. (OTCBB: DROP) is a life sciences company which has developed and maintains the rights to sublingual and transdermal delivery systems for the efficient delivery to humans of energy, medicines, vitamins and minerals.

The company recently announced a restructuring that could lead to a new business direction. Get the details by reading this report: http://bit.ly/-DROP-AnalystBrief

GNCC Capital, Inc. (OTCBB: GNCP) is a Diversified Holding Company which at present has Revenue Generating, Cash Positive and Profitable subsidiary companies which are engaged in the owning and operation of Adult Social Gaming Arcades based in South Florida. The Company also has significant assets in Gold & Silver Mining Exploration in Arizona.

GNCP has taken some restructuring steps intended to bolster specific existing operations. Read about these plans and actions in the report that follows: http://bit.ly/-GNCP-AnalystBrief

NanoViricides, Inc. (NYSE-MKT: NNVC) is a development stage company that is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide(R) class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them.

NNVC Has updated investors with information on some of its pipeline drugs and recent financial highlights. Read about here in this report: http://bit.ly/-NNVC-AnalystBrief

Sigma Labs, Inc. (OTCQB: SGLB) through its wholly-owned subsidiary B6 Sigma, Inc., develops and engineers advanced, in-process, non-destructive quality inspection systems for commercial firms worldwide seeking productive solutions for metal-based additive manufacturing or 3D printing, and other advanced manufacturing technologies.

The company has released information on product development and financial results for the period ended 9-30-14. Get the details when you read this report: http://bit.ly/-SGLB-AnalystBrief

Our new alert CANF was by far the #1 gainer in the entire AMEX exchange until about 3-3:15 PM when it became obvious that after we hit the 75% gains mark at $4.30/share, profit taking dominated the remainder of the trading session. Congrats to those who obviously pulled profits along the way.

In our original report below we mentioned Roth Capital Analyst Report had issued a $15 price target last year. That was actually upgraded based on clinical results afterward to a $28 target.

Small Cap IR was the first firm to notify its members of CANF on 11-18-2014 with a full due diligence report before market open.

An analyst report which includes an overview of the company, financial and competitive analysis, analyst recommendation and price target can be viewed in its entirety by using the link below. There is no cost obligation required to view this report.

http://bit.ly/-CANF-AnalystValuation

About Small Cap IR
Once you have read our reports written by financial analysts you will understand that we make every effort to provide informative equity research reports for interested parties.

3rd party chartered financial analysts (CFA’s) provide a straightforward assessment of the profiled company and have pledged to remain free of influence when writing research reports. They include stocks traded in the NYSE, NASDAQ, and OTCBB exchanges.

Forward-Looking Disclaimer
This report may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward- looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of mentioned company to be materially different from the statements made herein.

Compliance Procedure
Content is researched, written and reviewed on a best-effort basis by a 3rd party research analyst. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. We do not engage in high frequency trading.

A full disclaimer can be found by viewing the analyst report.

If you wish to have a company covered in more detail by our team, or wish to learn more about our services, please contact us at editor@smallcapir.com. For any urgent concerns or inquiries please contact us at editor@smallcapir.com.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

Source: Small Cap IR

Contact: editor@smallcapir.com